Antithrombotic therapy in patients with chronic heart failure: Rationale, clinical evidence and practical implications

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 2, 2007, Pages 224-231

  Dotsenko, O ^a   Kakkar, V V ^a  

^a THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Aspirin; Chronic heart failure; Thromboembolic events; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; PLACEBO; WARFARIN;

BLEEDING; BRAIN HEMORRHAGE; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DECELERATION; DISEASE PREDISPOSITION; DRUG ANTAGONISM; DRUG INDICATION; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART HEMODYNAMICS; HORMONAL REGULATION; HUMAN; INCIDENCE; INFLAMMATION; MORTALITY; NEUROENDOCRINE SYSTEM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINUS RHYTHM; STROKE; THROMBOEMBOLISM;

ANTICOAGULANTS; ASPIRIN; HEART FAILURE, CONGESTIVE; HUMANS; THROMBOEMBOLISM; WARFARIN;

EID: 33846406084     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02288.x     Document Type: Review

References (72)

1. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. Dallas (TX): The American Heart Association, 2005.
2. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJMD, Levy D. Lifetime risk for developing congestive heart failure: The Framingham Heart Study. Circulation 2002; 106: 3068-72.
3. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-402.
4. Lip GYH, Gibbs CR. Does heart failure confer a hypercoagulable state? J Am Coll Cardiol 1999; 33: 1424-6.
5. Kannel WB. Lessons from curbing the coronary artery disease epidemic for confronting the impending epidemic of heart failure. Med Clin North Am 2004; 88: 1129-33.
6. Yambe M, Tomiyama H, Hirayama Y, Gulniza Z, Takata Y, Koji Y, Motobe K, Yamashina A. Arterial stiffening as a possible risk factor for both atherosclerosis and diastolic heart failure. Hypertens Res 2004; 27: 625-31.
7. White R. The epidemiology of venous thromboembolism. Circulation 2003; 107: 4-8.
8. Coiffie G, Pozzoli M, Forni G, Franchini M, Opasich C, Cobelli F, Tavazzi L. Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients. Eur Heart J 1996; 17: 1381-9.
9. Katz SD, Marantz PR, Biasucci L, Jondeau G, Lee K, Brennan C, LeJemtel TH. Low incidence of stroke in ambulatory patients with heart failure: A prospective study. Am Heart J 1993; 126: 141-6.
10. Natterson PD, Stevenson WG, Saxon LA, Middlekauff HR, Stevenson LW. Risk of arterial embolization in 224 patients awaiting cardiac transplantation. Am Heart J 1995; 129: 564-70.
11. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with sinus rhythm: Evidence of gender difference in the studies of left ventricular dysfunction trial. J Am Coll Cardiol 1997; 29: 1074-80.
12. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87: 94-101.
13. Loh E, Sutton MJ, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moye LA, Goldhaber SZ, Pfeffer MA. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997; 336: 251-7.
14. Sirajuddin RA, Miller AB, Geraci SA. Anticoagulation in patients with dilated cardiomyopathy and sinus rhythm: A critical literature review. J Card Fail 2002; 8: 48-53.
15. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
16. Pullicino PM, Halperin JL, Thompson JL. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 2000; 25: 288-94.
17. Siachos T, Vanbakel A, Feldman DS, Uber W, Simpson KN, Pereira NL. Silent strokes in patients with heart failure. J Card Fail 2005; 11: 485-9.
18. Uretsky BF, Thygesen K, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M, Poole-Wilson PA, Ryden L. Acute coronary findings at autopsy in heart failure patients with sudden death: Results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000; 102: 611-16.
19. Steveson WG, Steveson LW, Middlekauff HR, Saxon LA. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation 1993; 88: 2953-61.
20. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-8.
21. Stratton JR. Left ventricular thrombosis and systemic emboli in myocardial infarction and cardiomyopathy. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Haemostasis and Thrombosis. Philadelphia, PA: Lippincott Williams & Wilkins, 2001: 1325-38.
22. Ciaccheri M, Castelli G, Cecchi F, Nannini M, Santoro G, Troiani V, Zuppiroli A, Dolara A. Lack of correlation between intracavity thrombus detected by cross-sectional echocardiography and systemic emboli in patients with dilated cardiomyopathy. Br Heart J 1989; 62: 26-9.
23. Blondheim DS, Jacobs LE, Kotler MN, Costacurta GA, Parry WR. Dilated cardiomyopathy with mitral regurgitation: Decreased survival despite a low frequency of left ventricular thrombus. Am Heart J 1991; 122: 763-71.
24. Falk HR, Foster E, Coats MH. Ventricular thrombi and thromboembolism in dilated cardiomyopathy: A prospective follow-up study. Am Heart J 1992; 123: 136-42.
25. Sharma ND, McCullough PA, Philbin EF, Weaver WD. Left ventricular thrombus and subsequent thromboembolism in patients with severe systolic dysfunction. Chest 2000; 117: 314-20.
26. Gottdiener JS, Gay JA, VanVoorhees L, DiBianco R, Fletcher RD. Frequency and embolic potential of left ventricular thrombus in dilated cardiomyopathy. Assessment by 2-dimensional echocardiography. Am J Cardiol 1983; 52: 1281-5.
27. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981; 47: 525-31.
28. Jafri SM. Hypercoagulability in heart failure. Semin Thromb Haemost 1997; 23: 543-5.
29. Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 1999; 33: 1424-6.
30. Lowe GD. The relationship between infection, inflammation, and cardiovascular disease: An overview. Ann Periodontol 2001; 6: 1-8.
31. Lopez JA, Kearon C, Lee AYY. Deep venous thrombosis. Hematology Am Soc Hematol Educ Program 2004; 1: 439-56.
32. Closse C, Seigneur M, Renard M, Pruvost A, Dumain P, Belloc F, Boisseau MR. Influence of hypoxia and hypoxia-reoxygenation on endothelial P-selectin expression. Thromb Res 1997; 85: 159-64.
33. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, Celi A, Croce K, Furie BC, Furie B. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticles P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197: 1585-98.
34. Myers DD, Hawley AE, Farris DM, Wrobleski SK, Thanaporn P, Schaub RG, Wagner DD, Kumar A, Wakefield TW. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg 2003; 38: 1075-89.
35. Furie B, Furie BC. Real time in vivo imaging of tissue factor-induced thrombus formation. Pathophysiol Haemost Thromb 2003; 33: 26-7.
36. Paulus WJ. Cytokines and heart failure. Heart Fail Monit 2000; 1: 50-6.
37. Dibbs Z, Kurrelmeyer K, Kalra D, Seta Y, Wang F, Bozkurt B, Baumgarten Y, Siyasubeamanian N, Mann DL. Cytokines in heart failure: Pathogenic mechanisms and potential treatment. Proc Assoc Am Physicians 1999; 111: 423-8.
38. Levi M, van der Poll T, ten Cate H, van Deventer SJ. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxemia. Eur J Clin Invest 1997; 27: 3-9.
39. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-5.
40. Biemond BJ, Levi M, ten Cate H, van der Poll T, Büller HR, Hack CE, ten Cate JW. Plasminogen activator and plasminogen activator inhibitor 1 release during experimental endotoxaemia in chimpanzees: Effect of interventions in the cytokine and coagulation cascades. Clin Sci 1995; 88: 587-94.
41. Levi M, Van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005; 15: 254-9.
42. Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland JG. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994; 127: 607-12.
43. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY. Endothelial dysfunction and damage in congestive heart failure: Relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 2004; 110: 1794-8.
44. Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm. Circulation 2001; 103: 1746-51.
45. Stumpf C, Lehner C, Eskafi S, Raaz D, Yilmaz A, Ropers S, Schmeisser A, Ludwig J, Daniel WG, Garlichs CD. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 2003; 5: 629-37.
46. Cugno M, Mari D, Meroni PL, Gronda E, Vicari F, Frigerio M, Coppola R, Bottasso B, Borghi MO, Gregorini L. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: Role of oral anticoagulants and successful heart transplantation. Br J Haematol 2004; 126: 85-92.
47. Lip GY. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol 1995; 26: 1757-8.
48. De Lorenzo F, Newberry D, Scully M, Kadziola Z, Dawson G, Saba N, Noorani A, Kashani S, Williams R, Kakkar VV. Low molecular weight Reparin (Bemiparin sodium) and the coagulation profile of patients with heart failure. Am Heart J 2002; 143: A8-A14.
49. Lip GYH, Lowe GD, Metcalfe MJ, Rumley A, Dunn FG. Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am J Cardiol 1995; 76: 453-8.
50. Griffith GC, Stragnell R, Levinson DC, Moore FJ, Ware AG. A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Ann Intern Med 1952; 37: 867-87.
51. Anderson GM, Hull E. The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. Am Heart J 1950; 39: 697-702.
52. Harvey WP, Finch CA. Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. N Engl J Med 1950; 242: 208-11.
53. Swedberg K, for the CONSENSUS trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
54. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: A cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol 1998; 31: 749-53.
55. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: A cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol 1998; 31: 419-25.
56. de Boer RA, Tjeerdsma G, Verheugt FW, van Veldhuisen DJ. Both antiplatelet and anticoagulant therapy favourably affect outcome in patients with advanced heart failure. A retrospective analysis of the PRIME-II trial. Thromb Res 2005; 116: 279-85.
57. Echemann M, Alla F, Briancon S, Juilliere Y, Virion JM, Mertes PM, Villemot JP, Zannad F, Aliot E, Breton CH, Khalif EK, Neimann JL, Allam S, Admant P, Baille N, Bellanger P, D'Hotel R, Dambrine P, Dodet JF, Graille M et.al. Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study). Eur J Heart Fail 2002; 4: 647-54.
58. Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF, Ezekowitz M, Jafri SM, O'Connor CM, Packer M, Schulman KA, Teo K, Warren S. The Warfarin and Antiplatelet Therapy in heart failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 2004; 10: 101-12.
59. Goldhaber SZ. The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial: A Report on a Presentation at the Late-Breaking Clinical Trials Session of the 53rd Annual Scientific Session of the American College of Cardiology; 7-10 March 2004; New Orleans (LA). Boston, MA: SNELL Medical Communication Inc., http://www.cardiologyupdate.org/crus/402-033.pdf (Accessed 8 November 2006).
60. Cleland JGF, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, Coletta AP. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronization therapy in heart failure. Eur J Heart Fail 2004; 6: 501-8.
61. Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, Prentice C, Ford I, Trainer A, Poole-Wilson PA. The Warfarin/Aspirin Study in heart failure (WASH): A randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004; 148: 157-64.
62. Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK, HELAS investigators. Efficacy of antithrombotic therapy in chronic heart failure: The HELAS study. Eur J Heart Fail 2006; 8: 428-32.
63. Pullicino O, Thrompson JL, Barton B, Levin B, Graham S, Freudenberger RS, on behalf of the WARCEF Investigators. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): Rationale, objectives, and design. J Card Fail 2006; 12: 39-46.
64. Lip GYH, Gibbs CR. Anticoagulation for heart failure in sinus rhythm: A Cochrane systematic review. Q J Med 2002; 95: 451-9.
65. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Chronic Heart Failure). Circulation 2005; 112: E154-235.
66. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
67. Cleland JGF, Loh H, Windram J. Some current controversies in heart failure (2004-2005). Minerva Cardioangiol 2004; 52: 465-77.
68. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction. Subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997; 79: 115-19.
69. Davie AP, Love MP, McMurray JJV. Even low dose aspirin inhibits arachidonic-acid induced vasodilatation in heart failure. Clin Pharm Ther 2000; 67: 530-7.
70. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary Tupdate 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-40.
71. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
72. Arnold JMO, Liu P, Demers C, Dorian P, Giannetti N, Haddad H, Heckman GA, Howlett JG, Ignaszewski A, Johnstone DE, Jong P, McKelvie RS, Moe GW, Parker JD, Rao V, Ross HJ, Sequeira EJ, Svendsen AM, Teo K, Tsuyuki RT, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management. Can J Cardiol 2006; 22: 23-45.